Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results at the International Congress of the Transplantation Society
ELDN•Company update
- Eledon Pharmaceuticals Inc. (ELDN.O) presented updated long-term Phase 2 Bestow extension study results at the International Congress of the Transplantation Society.
